Paradoxical reaction after switching between adalimumab biosimilars in a patient with psoriatic arthritis Mariano F. Palatnik, Emilce S. Fonseca, María Lorena Brance

A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales, Rafael Cáliz, Susana Aceituno, Miriam Prades, Carles Blanch

Anti-MDA5 dermatomyositis mimicking psoriatic arthritis Iván Cabezas-Rodríguez, Isla Morante-Bolado, Anahy Brandy-García, Rubén Queiro-Silva, Lourdes Mozo, Francisco Javier Ballina-García